Epstein-Barr prevention may reduce multiple sclerosis prevalence
These results indicate that efforts to prevent EBV infection may reciprocate to MS, which could have a substantial effect on…
By
CW and RW
Latest in
CW and RW
Further links between gut microbiome and immunotherapy outcomes in solid tumors found
Key questions continue to arise over the use of the gut microbiome in immunotherapy response when guiding treatment decisions.
By
Vutrisiran HELIOS-A results bolster its FDA application
According to Alnylam's HELIOS-A study, vutrisiran met all secondary endpoints for ATTR neuropathy, which will boost its presence in the…
By
Roche to reassess Huntington’s asset, reviving potential for younger patients
GlobalData believes that Roche’s bid to revive tominersen is justifiable given the acute unmet needs in the Huntington’s market.
By
Pfizer DMD fatality may clear the path for Sarepta’s gene therapy
The death of a participant in Pfizer's Phase lb study on PF-06939926 creates uncertainty around its future and may help…
By
Avrobio cancels Fabry disease gene therapy research programme following poor results
Despite earlier promising results, AVROBIO cancelled its FD therapy AVR-RD-01 following poor results from its Phase II clinical trial.
By
UNION’s orismilast enters Phase IIb and a crowded small molecule market
If approved, orismilast would be the second oral phosphodiesterase-4 inhibitor to enter the plaque psoriasis space.
By
Is precision medicine the future of obesity treatment?
Findings from a recent study could aid in the development of precision medicines for conditions such as obesity.
By